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A B S T R A C T
Objective: To evaluate platelet and White cell parameters in women with preeclampsia (PE) in comparison with a
healthy pregnancy.
Methods: A cross-sectional study was carried in 2015 at University of Gondar hospital. Thirty-three mild PE, 30
severe PE cases and 63 healthy pregnant women were enrolled in the study. About 3mL venous blood sample
was collected from each study participants. Hematological parameters were determined by Sysmex KX-21 he-
matological analyzer. Data normality was checked by Kolmogorov-Smirnov normality test. One way analysis of
variance with Bonferroni test and Pearson’s product moment correlation were done for normally distributed
data. For non-normally distributed data, Kruskal-Wallis H test with the Mann-Whitney U test and Spearman’s
rank-order Correlation test were done using SPSS 20.0 for Windows. A p-value<0.05 was considered as sta-
tistically signiﬁcant.
Results: The means of white blood cells (WBC), absolute Neutrophil count (ANC), Absolute middle cell count
(AMC), mean Platelet count (PTC), Platelet distribution width (PDW), neutrophil-to-lymphocyte ratio (NLR), and
median of platelet-to-large cell ratio (P-LCR) were signiﬁcantly increased; while Absolute lymphocyte count
(ALC) and platelet count (PTC) were signiﬁcantly decreased in PE groups. WBC, ANC, MPV, PDW, P-LCR and
NLR showed statistically signiﬁcant positive correlations, whereas PTC displayed a statistically signiﬁcant ne-
gative correlation with a MAP in PE group.
Conclusion: WBC, ANC, MPV, PDW, P-LCR and NLR were increased as PE advanced. PTC decreased with the
severity of the disease. Evaluation of these parameters as a supportive clinical marker in the assessment of
severity may assist the management of PE.
1. Introduction
Preeclampsia (PE), which is a pregnancy-speciﬁc multi-systemic
disorder, is a leading cause of morbidity and mortality for both mothers
and fetus [1]. It aﬀects 5–8% of all pregnancies and contributing to
50,000–60,000 annual maternal death globally [2]. In Ethiopia, about
54,000 up to 216,000 women are estimated to develop PE, and it is
responsible for 11% of all death of a mother and 16% of all direct
maternal death [3]. PE is characterized by the new development of
hypertension and proteinuria at ≥20weeks of pregnancy [1]. Without
proteinuria, it can be diagnosed by hypertension along with other di-
agnostic criteria [4].
Even though the aetiology and pathogenesis of PE continue to be
enigmatic, an exaggerated intravascular inﬂammatory response to
https://doi.org/10.1016/j.preghy.2018.06.006
Received 20 November 2017; Received in revised form 15 March 2018; Accepted 9 June 2018
Abbreviations: ALC, Absolute Lymphocyte Count; AMC, Absolute Middle cells Count; ANC, Absolute Neutrophil Count; ANOVA, Analysis of Variance; DBP, Diastolic
Blood Pressure; IQR, Interquartile Range; MAP, Mean Arterial Pressure; MPV, Mean Platelet Volume; MXD, Middle cells; NLR, Neutrophil-to-Lymphocyte ratio; PDW,
Platelet Distribution Width; PE, Preeclampsia; PLC, Percentage Lymphocyte Count; P-LCR, Platelet-Large Cell Ratio; PLR, Platelet-to-Lymphocyte Ratio; PMC,
Percentage Middle cells Count; PNC, Percentage Neutrophil Count; PTC, Platelet Count; SBP, Systolic Blood Pressure; SD, Standard Deviation; WBC, White Blood
Cells
⁎ Corresponding author.
1 These authors equally contributed to this work.
E-mail address: mulugeta.melku@gmail.com (M. Melku).
Pregnancy Hypertension 13 (2018) 242–247
Available online 09 June 2018
2210-7789/ © 2018 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved.
T
pregnancy is considered to be the major role player of PE [5,6]. Acti-
vations of platelets, leukocyte and systemic endothelial activation are
exaggerated in PE compared to normal pregnancy; and their interaction
supposed to result in the vascular damage in PE [7,8]. It has been
documented that leukocyte activation plays an important role in the
pathogenesis of PE [8]. A recent study revealed that the interactions of
platelets with diﬀerent cell types (endothelial, dendritic, T-lympho-
cytes, neutrophils and mononuclear phagocytes) can trigger and ex-
aggerate the inﬂammation in the arterial wall [9]. Thus, platelets may
involve in promoting an inﬂammatory response in PE through their
interaction with leukocytes and endothelium as crucial inﬂammatory
role players [2]. Endothelial dysfunction predates the beginning of
symptomatic clinical manifestations, which appears to be caused by the
exaggerated systemic inﬂammatory response. The central nervous
system, lung, liver, kidney, systemic vasculature, coagulation, heart,
placenta and fetus are subjected to exacerbated inﬂammation and en-
dothelial injury [10].
As its aetiology and pathogenesis remain unclear, there are no
speciﬁc preventive and treatment choices [11]. Delivery of fetus and
placenta are being described as the sole eﬀective treatment for PE [12].
Likewise, there are no clinical and laboratory-based models to predict
the occurrence of PE as well as the likelihood of detrimental outcomes
for mothers presenting with uncomplicated PE [13]. Still now, there is a
continuous search for eﬀective tools to predict the development and
severity of disease [14]. As stated by the International Society for the
Study of Hypertension in Pregnancy, the degree of proteinuria is ex-
cluded from the diagnostic criterion for assessment of severity of PE
because of its lesser value for further risk identiﬁcation though it assists
the diagnosis of PE. Accordingly, the hematological parameters and the
ratio of classes of blood cell (Platelet-to-Lymphocyte ratio(PLR) and the
Neutrophil-to-Lymphocyte ratio(NLR)), which have been recently ap-
plied to be systemic inﬂammatory response markers [15], could be
options for clinical evaluation of adverse maternal and fetal outcomes
in PE.
In PE, evaluating the changes in hematological parameters is es-
sential to prevent both maternal and fetal morbidity and mortality.
Estimating the variations in hematological parameters in PE compared
with a healthy pregnancy, and their relation with severity of disease has
paramount importance in assessing disease progression and managing
related complications. However, there is no much-published data de-
scribing hematological parameters with a degree of severity of PE in
Ethiopia. Therefore, this study was designed to assess changes in white
cell and platelet parameters in PE compared to healthy pregnancy, and
their relation with severity of the disease.
2. Methods and materials
2.1. Study design, setting and period
An institutional based cross-sectional analytical study was carried
out among pregnant women with PE attending antenatal care clinic and
admitted at the maternity ward, and healthy pregnant women who
were attending antenatal care service at antenatal care clinic,
University of Gondar Referral Hospital. The hospital is found in Gondar
town, northwest Ethiopia. It is at 727 km far away from Addis Ababa,
the capital city of Ethiopia. The hospital gives service to about 6 million
people. The study was done from February–August 2015.
2.2. Sample size and sampling technique
According to rules of thumb that have been recommended by van
Voorhis and Morgan, 30 participants per group are required to detect
real diﬀerences, which could lead to about 80% power [16]. Accord-
ingly, 126 study subjects (33 with mild PE, 30 with severe PE and 63
with healthy pregnancy as a control) were recruited into this study.
Healthy pregnant women voluntarily participated in the study and were
taken from study population by convenience i.e. sequential sampling
technique.
2.3. Source and study population
All pregnant women who had a follow-up care and pregnant women
with PE admitted at University of Gondar hospital maternity ward were
the source population. The study population were women with PE
at> 20weeks of gestation, and healthy pregnant women who were
matched for the age and gestational weeks.
2.4. Inclusion and exclusion criteria
Pregnant women with PE at> 20weeks of gestation, and age and
gestational age-matched normotensive women with uncomplicated
pregnancy were included in the study. Pregnant women who had a
history of smoking, epilepsy, hypertension, diabetes mellitus, chronic
systemic disease and chronic inﬂammatory disorders prior to pregnant
state; and those infected with clinically diagnosed infectious diseases
were excluded from the study. Pregnant women having ruptured
membranes, taking an anti-inﬂammatory (corticosteroids or non-ster-
oidal) and anticoagulants medication, and multiple pregnancies were
also excluded.
2.5. Operational deﬁnitions
Deﬁnition and classiﬁcation of PE were based on the re-
commendation of the American College of Obstetricians and
Gynecologists task force on hypertension in Pregnancy [4]. PE is de-
ﬁned as systolic blood pressure (SBP) ≥140 and/or a diastolic blood
pressure (DBP) ≥90mmHg on two measurements together with pro-
teinuria of≥1+ by dipstick in a random urine sample after 20 weeks of
pregnancy. PE is taken as mild if SBP/DBP is ≥140/90mmHg and
proteinuria of ≥1+ or more using dipstick after the 20 weeks of ge-
station in the absence of severe PE criteria. PE is considered as severe if
it presented with one or more of the following criteria: SBP
≥160mmHg or DBP≥110mmHg or both, new-onset cerebral or visual
disturbance, epigastric or right upper quadrant pain, pulmonary oe-
dema, and new onset seizures.
3. Data collection and laboratory methods
3.1. Socio-demographic and clinical data collection
Socio-demographic, family, medical and obstetric history data were
obtained by medical record review and face-to-face interview. Study
participants were interviewed with a structured questionnaire. Blood
pressure readings of study participants s were measured and recorded
using mercury sphygmomanometer according to the recommendation
of Hypertension Guideline Committee [17]. As a marker of PE severity,
mean arterial pressure (MAP) was calculated as DBP plus 1/3 of the
diﬀerence between SBP and DBP
3.2. Laboratory analysis
Fresh urine specimens were collected in a clean dry container.
Proteinuria was determined by Cromatest® Linear URS-10 strips (Linear
Chemicals S.L, 08390 Montgat (Barcelona), Spain). Three ml venous
blood sample was collected into vacutainer tube with an ethylene-
diaminetetra-acetic acid anticoagulant. Hematological parameters were
determined by Sysmex KX-21(Sysmex Corporation, Kobe, Japan) au-
tomated hematology analyzer within 1-h blood sample collection. All
procedures were conducted according to the manufacturers’ instruction
manual.
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3.3. Ethical consideration
Before commencement of the study, the study was ethically ap-
proved by School of Biomedical and Laboratory Sciences Research and
Ethical Committee (Reference number: SBMLS/927/07). Permission
letter was obtained from the administrator of University of Gondar
hospital. Each study participants were requested to participate vo-
luntarily. Written informed consent was obtained from each study
participants. Voluntary participation and the right to withdraw were
assured for each participant. Privacy and conﬁdentiality were main-
tained during and/or after the interview. The laboratory results were
communicated to the authorized clinicians.
3.4. Data analysis and interpretation
Data were coded and cleaned before data analysis. Data analysis
was performed using SPSS 20.0 for Windows (SPSS Inc., Chicago, IL,
USA). The Kolmogorov-Smirnov normality test was run for checking the
distribution of hematological parameters and the Levene statistic test
was used to test the homogeneity of variances. One way analysis of
variance test and Bonferroni pairwise comparison tests were conducted
for comparison of normally distributed variables. The results of nor-
mally distributed variables are presented as the mean ± standard de-
viation (SD). Kruskal-Wallis H test in conjunction with the Mann-
Whitney U test was used for comparison of non-normally distrusted
hematological parameters, and the results are presented as median and
Interquartile Range (IQR). For the evaluation of the correlations of
parameters with a MAP, Spearman’s rank-order Correlation test was
used. A p-value<0.05 was considered as statistically signiﬁcant for all
analyses. The results of the study were summarized using tables and
texts.
4. Results
4.1. Characteristics of study participants
The median [IQR] age of the control and PE group was 26.00[6.00]
and 25.00[8.00] years, respectively. In this study, no statistically sig-
niﬁcant diﬀerences between the control and PE groups in age, number
of pregnancies (gravidity), number of deliveries (parity) and gestational
weeks were observed as outlined in Table 1.
4.2. White cell parameters
The mean (± SD) WBC, ANC and NLR have shown signiﬁcant
elevation in women with PE as compared to control group. But ALC was
signiﬁcantly decreased in PE group than the control group. The median
[IQR] AMC (Middle cells: basophils, eosinophils and monocytes) has
shown signiﬁcant elevation in PE group as compared to the control
group (P < 0.001) (Table 2).
In Bonferroni pairwise comparison tests between groups, there were
statistically signiﬁcant diﬀerences between the three groups of the
study population with regard to the mean WBC, ANC and NLR, which
were signiﬁcantly increased with the severity of PE (p < 0.05).
However, no signiﬁcant diﬀerence was found between mild and severe
PE (p=0.65), while a signiﬁcant diﬀerence was observed between
mild PE and the control group (p=0.044), and severe PE and the
control group (p=0.043) for mean ALC. In Mann-Whitney U test
pairwise comparisons, there was no a signiﬁcant diﬀerence between
mild and severe PE (p=0.109), while signiﬁcant diﬀerence was de-
tected between mild PE and the control group (P=0.007) and severe
PE and the control group (P < 0.001) in median(IQR) AMC value
(Table 3).
4.3. Platelet parameters
As presented in Table 4, the mean ± SD platelet count (PTC) was
signiﬁcantly lower in PE group (158.38 ± 42.71× 103/µL) compared
to the control group (194.05 ± 45.59×103/µL). Whereas mean pla-
telet volume (MPV) and platelet distribution width (PDW) were sig-
niﬁcantly higher in PE group (11.28 ± 0.97 fL and 16.06 ± 2.44 fL,
respectively) than the control group (10.31 ± 1.13 fL and
14.01 ± 2.54 fL, respectively) in ANOVA test. In Mann-Whitney U test,
median [IQR] platelet large cell ratio (P-LCR) level was also sig-
niﬁcantly higher in PE (35.00[10.20]%) than the control group
(27.00[11.10] %).
In Bonferroni pairwise comparison tests between groups, there were
statistically signiﬁcant diﬀerences among the control, mild and severe
PE groups with regard to PTC which showed a declining value with the
severity of disease, whereas MPV and PDW signiﬁcantly increased with
the severity of PE. Moreover, the mean value of P-LCR has shown a
signiﬁcant elevation in severe PE group compared to the control group.
In Kruskal-Wallis H test and Mann-Whitney U test pairwise compar-
isons, the median P-LCR has shown signiﬁcant diﬀerences among the
three groups; signiﬁcantly elevated as the disease severity advances
(Table 5).
4.4. Correlation analysis
For assessment of the association of hematological parameters with
the severity of disease, their correlation with the MAP was computed in
mild and severe PE groups for those parameters that showed signiﬁcant
diﬀerences between PE groups. In correlation analysis, a MAP showed
statistically signiﬁcant positive correlations with WBC (rho= 0.52),
ANC (rho=0.51), MPV (rho=0.37), PDW (rho=0.43), P-LCR
(rho=0.44) and NLR (rho=0.31) in PE group. Similarly, it showed
statistically signiﬁcant negative correlation with PTC (rho=−0.33)
(Table 6).
5. Discussion
PE is one of the commonest grave complications of pregnancy [18]
and a signiﬁcant health problem, which needs a due attention parti-
cularly in developing nations where the risk of adverse outcomes are
high [19]. The aetiology and pathogenesis of PE continue to be blurred
in the face of exhaustive research eﬀorts [5]. However, extensive sys-
temic maternal inﬂammatory response and endothelial cell dysfunction
recently have been proposed to be critical players [18]. Currently, there
are no available tests for the clinical diagnosis of PE based on tests that
drown from its’ etiopathogenesis [1]. Likewise, there is no laboratory
method to assess the likelihood of detrimental outcomes for mothers
presenting with uncomplicated PE. This study was performed to eval-
uate white blood cell and platelet parameters as well as the two derived
parameters, NLR and PLR, based on the information that PE is an in-
ﬂammatory disease.
In this study, we observed statistically signiﬁcant elevated leukocyte
and neutrophil count in PE group as compared to the control group (p-
Table 1
Characteristics of healthy pregnant women and preeclamptic women partici-
pated in the study (n= 126).
Characteristics Healthy pregnancy
(median[IQR]) (n= 63)
PE (median[IQR])
(n= 63)
P-value
Age (in years) 26.00[6.00] 25.00[8.00] 0.319
Number of
pregnancy
2.00[2.00] 1.00[1.00] 0.257
Number of delivery 1.00[1.00] 1.00[1.00] 0.120
Gestational age (in
weeks)
37.00[4.50] 37.60[3.80] 0.075
SBP (mmHg) 110.00[10.00] 150.00[10.00] < 0.001
DBP (mmHg) 70.00[15.00] 100.00[10.00] < 0.001
MAP (mm Hg) 83.33[11.67] 120.00[6.67] < 0.001
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value<0.05). Similar ﬁndings have been reported by Alisi P. Nc et al
[20], Ghosh et al [21], Mihu et al [22], and Ünlü1 et al [6]. Our study is
also in consonance with the study that corroborates an exaggerated
inﬂammatory response in PE than healthy pregnancy [7]. Tough it was
not statistically signiﬁcant, Ceyhan et al. reported that the mean WBC
count was higher in PE compared to the control group [23]. In the
above study, small numbers of study subjects relative to our sample size
were enrolled. This could be the probable explanation for the observed
discrepancy between Ceyhan et al and our ﬁnding. Our observation in
the neutrophil count is similar to report of Alisi et al who observed a
statistically signiﬁcant increase in women with PE compared with the
control group [20]. Neutrophil count in the present study is also con-
sistent with the results of previous studies [21,22]. Moreover, statisti-
cally signiﬁcant higher ANC has been reported by Canzoneri et al [8]
who proposed that leukocytosis noticed in PE would be as a result of
increment in the number of neutrophils.
Statistically signiﬁcant changes in WBC and neutrophil counts were
also observed when PE groups were compared with each other and with
the control group. Our result is in agreement with previous studies
which demonstrated that increased values in severe PE compared to the
Table 2
Comparisons of total and diﬀerential WBC count between healthy pregnant and preeclamptic women.
WBC parameters Healthy pregnancy (n=63) PE (n= 63) P value
Total WBC (×103/µL)© 8.18 ± 2.05 10.71 ± 3.49 <0.001
Absolute neutrophil count (ANC)(×103/µL)© 5.56 ± 1.54 7.92 ± 2.86 <0.001
Absolute lymphocyte count (ALC)(×103/µL)© 1.92 ± 0.45 1.70 ± 0.32 0.003
Absolute middle cells count (AMC)(×103/µL)© 0.70[0.30] 1.00[0.70] <0.001
Percentage neutrophil count (PNC) (%)© 67.64 ± 3.68 73.27 ± 4.04 <0.001
Percentage lymphocyte count (PLC) (%)© 23.61 ± 3.25 16.93 ± 4.15 <0.001
Percentage mixed count (PMC) (%)® 8.20[2.50] 9.80[2.70] 0.002
Neutrophil-to-lymphocyte ratio (NLR)© 2.92 ± 0.50 4.67 ± 1.50 <0.001
© Data were expressed as Mean ± SD.
® Data were expressed as Median(IQR).
Table 3
Comparisons of total and diﬀerential WBC count between women healthy pregnancy, mild PE and severe PE.
WBC parameters Healthy Pregnancy (n= 63) Mild PE (n= 33) Severe PE (n= 30) ¤P value *P value **P Value ***P value
Total WBC (×103/µL)© 8.18 ± 2.05 9.84 ± 3.22 11.66 ± 3.57 < 0.001 <0.001 0.02 0.033
ANC (×103/µL)© 5.56 ± 1.54 7.12 ± 2.47 8.81 ± 3.02 < 0.001 <0.001 0.004 0.009
ALC (×103/µL)© 1.92 ± 0.45 1.71 ± 0.37 1.70 ± 0.28 0.012 0.044 0.043 0.65
AMC (×103/µL)® 0.70(0.30) 0.90(0.75) 1.10(0.62) < 0.001 <0.001 0.007 0.109
PNC (%)© 67.64 ± 3.68 72.14 ± 3.55 74.52 ± 4.24 < 0.001 <0.001 <0.001 0.043
PLC (%)© 23.61 ± 3.25 18.09 ± 3.88 15.66 ± 4.13 < 0.001 <0.001 <0.001 0.057
PMC (%)® 8.20[2.50] 9.80[4.25] 9.85[2.23] 0.006 0.003 0.03 0.951
NLR© 2.92 ± 0.50 4.05 ± 1.13 5.21 ± 1.68 < 0.001 <0.001 <0.001 <0.001
*P value of comparison of severe PE and healthy pregnancy in a pairwise comparison test.
**P value of comparison of mild PE to healthy pregnancy in a pairwise comparison test.
***P value of comparison of severe PE to mild PE in a pairwise comparison test.
PNC: percentage of a neutrophil count; PLC: percentage of lymphocyte count; PMC: percentage of middle cell count.
¤ P value of comparison among healthy pregnancy, mild PE and severe PE groups.
© Data were expressed as Mean ± SD.
® Data were expressed as Median[IQR].
Table 4
Comparisons of platelet parameters between healthy pregnant and pre-
eclamptic women.
Platelet parameters Healthy Pregnancy
(n=63)
PE (n= 63) P value
PTC(×103/µL)© 194.05 ± 45.59 158.38 ± 42.71 < 0.001
MPV(fL)© 10.31 ± 1.13 11.28 ± 0.97 < 0.001
PDW(fL)© 14.01 ± 2.54 16.06 ± 2.44 < 0.001
P-LCR (%)® 27.00[11.10] 35.00[10.20] < 0.001
Platelet-to-lymphocyte
ratio(PLR) ©
108.08 ± 40.30 96.94 ± 33.96 0.097
© Data were expressed as Mean ± SD.
® Data were expressed as median(IQR).
Table 5
Pairwise Comparisons of platelet parameters among women with healthy pregnancy, mild and severe preeclampsia.
Platelet parameters Healthy pregnancy (n= 63) Mild PE (n= 33) Severe PE (n=30) ¤P value *P value **P value ***P value
PTC(×103/µL)© 194.05 ± 45.59 171.06 ± 36.91 144.43 ± 44.86 < 0.001 <0.001 0.045 0.049
MPV(fL)© 10.31 ± 1.13 10.97 ± 1.13 11.61 ± 0.63 < 0.001 <0.001 0.011 0.045
PDW(fL)© 14.01 ± 2.54 15.30 ± 2.54 16.90 ± 2.07 < 0.001 <0.001 0.045 0.032
P-LCR (%)® 27.00[11.10] 33.30[11.10] 37.50[8.18] < 0.001 <0.001 0.007 < 0.001
PLR© 108.08 ± 40.30 102.50 ± 33.54 87.67 ± 32.45 0.04 0.042 0.69 0.175
*P value of comparison of severe PE and healthy pregnancy in a pairwise comparison test.
**P value of comparison of mild PE to healthy pregnancy in a pairwise comparison test.
***P value of comparison of severe PE to mild PE in a pairwise comparison test.
¤P value of comparison among healthy pregnancy, mild PE and severe PE groups.
© Data were expressed as Mean ± SD.
® Data were expressed as Median [IQR].
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control group [8,15]. Gosh et al. has similarly reported a higher WBC
count in severe PE than the control group, which in line with our study
[21]. In addition, the obtained statistically signiﬁcant higher mean
values of WBC and neutrophil count in severe when compared to mild
PE, and in mild PE compared to the control group agreed with previous
studies [8,21]. In contrast to our ﬁnding, no signiﬁcant diﬀerences
observed between mild PE and healthy pregnancy in WBC and neu-
trophil count in the study of Canzoneri et al [8]. There is also evidence
that substantiates high activation of leukocytes in maternal circulation
and in the placental bed as well during PE [22].
In the present study, ALC was signiﬁcantly reduced in PE group
compared to the control group. The result is in agreement with Alisi P
et al. and Lurie et al report [20]. But, the result is diﬀerent from a study
done by Canzoneri et al that they didn’t found a statistically signiﬁcant
diﬀerence in ALC between PE group and the control group [8]. Evi-
dence suggests that abnormal activation of the immune system may
play a role in the aetiology and pathogenesis of PE. The deﬁciency of
regulatory T cell has shown to cause activation of T-helper 1, ultimately
the innate immunity. The changes in the innate immunity can also in-
ﬂuence the T-helper 1 / regulatory T cell cytokine proﬁle, leading to the
activation of peripheral blood granulocytes and deﬁciency of peripheral
blood lymphoid cells [24].
A signiﬁcant decline of PTC shown in PE compared to the control
group is in harmony with the ﬁndings of previous studies [14,25].
However, in some studies [6,23], statistically signiﬁcant diﬀerence was
not observed between the two groups. In agreement with previous re-
ports [6,25], the value of MPV was signiﬁcantly higher in PE group
compared to the control group. Similarly, PDW and P-LCR were sig-
niﬁcantly higher in PE group, which is consistent with the result of the
previous study [25]. In multiple pairwise comparisons of the current
study, the PTC in severe PE was signiﬁcantly lower when compared to
the control group. This result was similar to many previously reported
studies [8,26]. While the value of MPV, PDW and P-LCR were sig-
niﬁcantly higher in severe PE compared to the control group. In
agreement with this ﬁnding, the earlier study also reported an elevated
P-LCR, MPV and PDW [26]. The same study has also reported that re-
duced PTC, and increased MPV, PDW and P-LCR were found in mild PE
group compared with the control group [26]. Thus, these ﬁndings have
supported our study in which we revealed comparable results. How-
ever, Yang et al was not observed signiﬁcant variations of PTC between
severe PE and the control groups [27]. Comparing to mild PE, de-
creased PTC, and increased MPV, PDW and P-LCR values were seen in
severe PE, which is in agreement with previous reports [26,27]. In PE,
the lifespan of platelets decrease from 3 to 5 days, and the aggregation
and destruction of platelets occur as a result of the altered membrane
structure of platelets [28]. These mechanisms could be the possible
reason for the observed decrease in PTC among PE group. Endothelial
damage and peripheral consumption may also cause thrombocytopenia
in PE. The increase in MPV and PDW in mild and severe PE most likely
points out increased platelet turn over which could substantiate the
evidence that platelet survival time is decreased, resulting in the in-
creased destruction of platelets [26,29]. The elevation of P-LCR levels
in PE group could indicate high bone marrow activity [26]. Many
studies proposed that activated platelets become larger in size resulting
in higher platelet indices; for instance, MPV, PDW and P-LCR
[26,29,30].
Endothelial dysfunction and inﬂammation are essential mechanisms
for the establishment and progression of atherosclerosis and PE [30]. As
Turkmen et al cited in their study, NLR and PLR were demonstrated in
numerous studies as new inﬂammation markers in cardiac and non-
cardiac diseases mediated by the inﬂammatory process [9]. However,
there is no previous reports detailing the role of PLR and NLR in PE. The
result from the present study has shown a statistically signiﬁcant higher
NLR level in PE group compared with the control group. This result is
consistent with the ﬁnding of a previous study done by Oylumlu et al
[30], but it is diﬀerent from the ﬁnding of Yavuzcan et al. [15] who
found no signiﬁcant diﬀerence between PE group and the control
group. The possible reason for the discrepancy might be attributed to
the retrospective design that Yavuzcan et al used, as the confounding
factors might not be properly controlled in a retrospective design. It is
also noticed that NLR has shown a signiﬁcant rise as the disease ad-
vances. As to PLR, signiﬁcant elevation was noticed in severe PE group
compared to the control. However, Yavuzcan et al. [15] were not found
a signiﬁcant diﬀerence in the mean value of PLR between severe PE
group and the control group. This needs further experimental studies to
explore the biological mechanisms how PE inﬂuences NLR and PLR.
In this study, it has been observed that WBC, ANC and NLR were
signiﬁcantly correlated with a MAP in PE group. MAP, as an indicator
of disease severity, has been signiﬁcantly and positively correlated with
total WBC and ANC, which is nearly similar to Mihu et al. [22] study
that reported a signiﬁcant positive correlation of leukocytes and DBP,
and neutrophils and DBP. In platelet parameters analysis, PTC has
shown a statistically signiﬁcant negative correlation, while MPV, PDW
and P-LCR have shown positive correlations with a MAP in PE group.
Nevertheless, only one study, as far as we know, has been done re-
garding correlations of platelet parameters with the MAP as an index of
disease severity, in which a statistically notable positive correlation has
been demonstrated between PDW and MAP [27]. A prospective study,
in which DBP was used as diagnostic criteria, revealed a strongest ne-
gative correlation between PTC and blood pressure, whereas MPV and
PDW were found to be correlated with blood pressure in the positive
direction [14].
5.1. Limitation
The major limitation of this study is that it is a single-centre study
which can limit its generalizability of the result to the population in the
area. Another limitation of this study is that the sample size is not large.
This may also limit the statistical power of the study. The cross-sec-
tional nation of the study design does not also establish cause-eﬀect-
relationship, so that which appeared ﬁrst, either PE or hematological
parameter changes, remained dilemmatic.
6. Conclusion
In conclusion, the study demonstrates that signiﬁcantly increased
values of total WBC, ANC, NLR, MPV, PDW AMC, and P-LCR; and sig-
niﬁcantly reduced values of PTC and ALC were found in PE compared to
the control group. Moreover, total WBC, ANC, NLR, MPV, PDW and P-
LCR were positively correlated with a MAP, whereas PTC was nega-
tively correlated with a MAP in PE group. Hence, monitoring of he-
matological parameters can be used as clinical indicators in the as-
sessment of severity of PE and may be taken as a useful parameter to
prevent complications of PE. However, further multicenter prospective
Table 6
Spearman's rank-order correlations of WBC, ANC, PTC, MPV, PDW, P-LCR and NLR with a MAP in preeclamptic women (n= 63).
Parameters WBC (×103/µL) ANC (×103/µL) PTC (×103/µL) MPV(fL) PDW (fL) P-LCR NLR
Correlation coeﬃcient (rho) 0.52** 0.51** −0.33** 0.37** 0.43** 0.44** 0.31**
P value < 0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.01
**rho is signiﬁcant at the 0.01 level (2-tailed).
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cohort studies with large sample size are required to verify the role
these parameters in the diagnosis of PE and assessment of disease se-
verity.
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